https://www.selleckchem.com/pr....oducts/atogepant.htm
CD226 blockade reduced CD107a+, IFN-γ+, and TNF-α+ proportions among CD8+CD226+ T cells, inhibiting CD8+ T cell proliferation. In conclusion, CD226/TIGIT immune checkpoint imbalance is involved in the pathogenesis of PBC. The CD226/TIGIT ratio of CD8+ T cell is a potential biomarker for evaluating the disease status and the prognosis of PBC patients. Moreover, CD8+CD226+ T cells represent a possible therapeutic target for PBC, and blocking CD226 could inhibit the activity of this cell subset in vitro.Kawasaki disease (KD) was first de
Aimer
Commentaire
Partagez
